Mereo BioPharma (MREO) Total Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has reported Total Current Liabilities for 10 consecutive years, with $5.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 24.88% year-over-year to $5.7 million in Q2 2026; TTM through Jun 2026 was $5.7 million, a 24.88% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 68.93% from the prior year.
• Total Current Liabilities was $5.7 million for Q2 2026 at Mereo BioPharma, down from $6.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $44.3 million in Q2 2022 and troughed at $4.3 million in Q4 2025.
• A 5-year average of $14.0 million and a median of $10.2 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 221.32% in 2022 and plunged 68.93% in 2025, its largest moves.
• Over 5 years, Total Current Liabilities stood at $28.9 million in 2022, then tumbled by 67.23% to $9.5 million in 2023, then surged by 45.98% to $13.8 million in 2024, then plunged by 68.93% to $4.3 million in 2025, then jumped by 31.96% to $5.7 million in 2026.
• The last three Total Current Liabilities figures came in at $5.7 million (Q2 2026), $6.2 million (Q1 2026), and $4.3 million (Q4 2025), per Business Quant data.